<DOC>
	<DOC>NCT00838916</DOC>
	<brief_summary>A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>type 2 diabetes BMI 2045kg/m2 inclusive females who are pregnant, lactating or within &lt;6 weeks postpartum current symptomatic heart failure (NYHA Class IIIIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>diabetes</keyword>
</DOC>